High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.
Fifty six patients, with histologically confirmed cancer, who received highly emetogenic chemotherapy, were entered on a randomized double blind, low versus high dose, study of granisetron, a 5HT3 receptor antagonist. A single dose of intravenous granisetron protected the majority of patients from nausea and vomiting, 160 micrograms/kg was more effective than 40 micrograms/kg with no more side effects. Additional doses of granisetron conferred added benefit to patients who experienced breakthrough symptoms. Granisetron at a dose range of 40-240 micrograms/kg over a 24 hour period was well tolerated with the only side effect being mild headache.
Falkson
H C
HC
Department of Medical Oncology, University of Pretoria, South Africa.
Falkson
C I
CI
Falkson
G
G
D000970:Antineoplastic Agents / Q000009:adverse effects*; D004311:Double-Blind Method; D015507:Drugs, Investigational / Q000008:administration & dosage*; D005260:Female; D017829:Granisetron; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D011897:Random Allocation; D012702:Serotonin Antagonists / Q000008:administration & dosage*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D017829:Granisetron; D007191:Indazoles; D012702:Serotonin Antagonists